Prognostic Impact of CD44 Expression in Patients With Myxofibrosarcoma

Overview

Journal In Vivo

Specialty Oncology

Date 2019 Oct 31

PMID 31662543

Citations 3

Authors

Hiroyuki Tsuchie

Makoto Emori

Naohisa Miyakoshi

Hiroyuki Nagasawa

Kyoji Okada

Hiroshi Nanjyo

Yasutaka Murahashi

Emi Mizushima

Junya Shimizu

Toshihiko Yamashita

Yoichi Shimada

Affiliations

Soon will be listed here.

Abstract

Background/aim: Abnormal expression of CD44 may promote cancer invasion. However, a limited number of studies have investigated the expression of CD44 in soft tissue sarcoma such as myxofibrosarcoma. We evaluated the relationship between expression of the standard form of CD44 (CD44s) and the clinical course of myxofibrosarcoma.

Materials And Methods: Forty-four myxofibrosarcoma patients were retrospectively enrolled. Patient information including the proportion of CD44s-positive cells was collected, and multivariate analyses were conducted to determine the relationship between CD44s expression and clinicopathological factors.

Results: Although CD44s did not affect prognosis, multivariate analysis indicated that high expression of CD44s predicted poor event-free survival (p=0.004) and local recurrence (p=0.049). CD44s expression was not associated with the occurrence of distant metastasis but was significantly higher in those with lung metastasis (p=0.044).

Conclusion: Increased expression of CD44s predicted poor event-free survival and local recurrence and was observed in myxofibrosarcoma patients with lung metastasis.

Citing Articles

CD44 In Sarcomas: A Comprehensive Review and Future Perspectives.

Fernandez-Tabanera E, Melero-Fernandez de Mera R, Alonso J Front Oncol. 2022; 12:909450.

PMID: 35785191 PMC: 9247467. DOI: 10.3389/fonc.2022.909450.

Analysis of prognostic factors in 171 patients with myxofibrosarcoma of the trunk and extremities: a cohort study.

Liu H, Zhang X, Zhang S, Yu S Ann Transl Med. 2021; 9(16):1322.

PMID: 34532459 PMC: 8422150. DOI: 10.21037/atm-21-3587.

CD44 as a tumor biomarker and therapeutic target.

Xu H, Niu M, Yuan X, Wu K, Liu A Exp Hematol Oncol. 2020; 9(1):36.

PMID: 33303029 PMC: 7727191. DOI: 10.1186/s40164-020-00192-0.

References

Sanfilippo R, Miceli R, Grosso F, Fiore M, Puma E, Pennacchioli E . Myxofibrosarcoma: prognostic factors and survival in a series of patients treated at a single institution. Ann Surg Oncol. 2010; 18(3):720-5. DOI: 10.1245/s10434-010-1341-4. View

Gvozdenovic A, Arlt M, Campanile C, Brennecke P, Husmann K, Li Y . CD44 enhances tumor formation and lung metastasis in experimental osteosarcoma and is an additional predictor for poor patient outcome. J Bone Miner Res. 2012; 28(4):838-47. DOI: 10.1002/jbmr.1817. View

Engellau J, Bendahl P, Persson A, Domanski H, Akerman M, Gustafson P . Improved prognostication in soft tissue sarcoma: independent information from vascular invasion, necrosis, growth pattern, and immunostaining using whole-tumor sections and tissue microarrays. Hum Pathol. 2005; 36(9):994-1002. DOI: 10.1016/j.humpath.2005.07.008. View

Li Y, Heldin P . Hyaluronan production increases the malignant properties of mesothelioma cells. Br J Cancer. 2001; 85(4):600-7. PMC: 2364109. DOI: 10.1054/bjoc.2001.1922. View

Look Hong N, Hornicek F, Raskin K, Yoon S, Szymonifka J, Yeap B . Prognostic factors and outcomes of patients with myxofibrosarcoma. Ann Surg Oncol. 2012; 20(1):80-6. PMC: 3837421. DOI: 10.1245/s10434-012-2572-3. View

Joensuu H, Klemi P, Toikkanen S, Jalkanen S . Glycoprotein CD44 expression and its association with survival in breast cancer. Am J Pathol. 1993; 143(3):867-74. PMC: 1887197. View

Deng Z, Niu G, Cai L, Wei R, Zhao X . The prognostic significance of CD44V6, CDH11, and β-catenin expression in patients with osteosarcoma. Biomed Res Int. 2013; 2013:496193. PMC: 3732612. DOI: 10.1155/2013/496193. View

Matuschek C, Lehnhardt M, Gerber P, Poremba C, Hamilton J, Lammering G . Increased CD44s and decreased CD44v6 RNA expression are associated with better survival in myxofibrosarcoma patients: a pilot study. Eur J Med Res. 2014; 19:6. PMC: 3942188. DOI: 10.1186/2047-783X-19-6. View

Mutter R, Singer S, Zhang Z, Brennan M, Alektiar K . The enigma of myxofibrosarcoma of the extremity. Cancer. 2011; 118(2):518-27. PMC: 3360945. DOI: 10.1002/cncr.26296. View

10.

Liu Y, Wu Y, Gu S, Sun Z, Rui Y, Wang J . Prognostic role of CD44 expression in osteosarcoma: evidence from six studies. Diagn Pathol. 2014; 9:140. PMC: 4261773. DOI: 10.1186/1746-1596-9-140. View

11.

Washimi O, Ueda R, Ariyoshi Y, Suyama M, Seki T, Takahashi T . Expression of CD44 variant isoforms in normal and neoplastic cells of the lung. Jpn J Cancer Res. 1994; 85(11):1112-6. PMC: 5919360. DOI: 10.1111/j.1349-7006.1994.tb02915.x. View

12.

He A, Yang X, Huang Y, Feng T, Wang Y, Sun Y . CD133(+) CD44(+) Cells Mediate in the Lung Metastasis of Osteosarcoma. J Cell Biochem. 2015; 116(8):1719-29. DOI: 10.1002/jcb.25131. View

13.

Heyse T, Malcherczyk D, Moll R, Timmesfeld N, Wapelhorst J, Fuchs-Winkelmann S . CD44: survival and metastasis in chondrosarcoma. Osteoarthritis Cartilage. 2010; 18(6):849-56. DOI: 10.1016/j.joca.2010.02.007. View

14.

Nihei Z, Ichikawa W, Kojima K, Togo S, Miyanaga T, Hirayama R . The positive relationship between the expression of CD44 variant 6 and prognosis in colorectal cancer. Surg Today. 1996; 26(9):760-1. DOI: 10.1007/BF00312104. View

15.

Manoso M, Pratt J, Healey J, Boland P, Athanasian E . Infiltrative MRI pattern and incomplete initial surgery compromise local control of myxofibrosarcoma. Clin Orthop Relat Res. 2006; 450:89-94. DOI: 10.1097/01.blo.0000229292.98850.14. View

16.

Humphrey G, Hazel D, MacLennan K, Lewis I . Expression of CD44 by rhabdomyosarcoma: a new prognostic marker?. Br J Cancer. 1999; 80(5-6):918-21. PMC: 2362272. DOI: 10.1038/sj.bjc.6690442. View

17.

Bizet A, Liu K, Tran-Khanh N, Saksena A, Vorstenbosch J, Finnson K . The TGF-β co-receptor, CD109, promotes internalization and degradation of TGF-β receptors. Biochim Biophys Acta. 2011; 1813(5):742-53. DOI: 10.1016/j.bbamcr.2011.01.028. View

18.

Sneath R, Mangham D . CD44 isoform expression in synovial sarcoma correlates with epitheliogenesis but not prognosis. Histopathology. 2000; 37(2):166-74. DOI: 10.1046/j.1365-2559.2000.00953.x. View

19.

Kuryu M, Ozaki T, Nishida K, Shibahara M, Kawai A, Inoue H . Expression of CD44 variants in osteosarcoma. J Cancer Res Clin Oncol. 1999; 125(11):646-52. DOI: 10.1007/s004320050329. View

20.

Henderson T, Chen M, Darrow M, Li C, Chiu C, Monjazeb A . Alterations in cancer stem-cell marker CD44 expression predict oncologic outcome in soft-tissue sarcomas. J Surg Res. 2018; 223:207-214. PMC: 5812363. DOI: 10.1016/j.jss.2017.11.016. View